2024-516692-32-00CompletedPhase 1
A study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and pertuzumab in adult patients with refractory metastatic Her2 positive breast cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 19 Feb 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 18 Oct 2024
- Start date
- 26 May 2022
- Lead sponsor
- Vall D Hebron Institute Of Oncology
- Diseases
- Metastatic breast cancer
- EU CT number
- 2024-516692-32-00
- EudraCT number
- 2020-004543-84
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 20
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Completed |
| Hospital del Mar | Barcelona | Spain | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.